In addition, two large randomized clinical trials (RCTs) of GLP-1RA in patients with T1DM were conducted to evaluate the use of liraglutide 1.8 mg daily compared to placebo as an add-on to standard insulin therapy. This evidence concerns the gene INS and type 1 diabetes mellitus.